Solid Biosciences Inc. (SLDB)

Over the past six months, Solid Biosciences' stock has been impacted by insider selling, analyst coverage initiation, clinical trial progress, regulatory milestones, and financial reports. Several executives sold shares to cover withholding taxes following the vesting of restricted stock units. Needham initiated coverage with a "Buy" recommendation. The Phase 1/2 INSPIRE DUCHENNE trial for Duchenne muscular dystrophy has dosed 33 participants, with the therapy generally well tolerated. Solid Biosciences received Orphan Drug designation from the U.S. FDA for SGT-212. The Q3 2025 report showed a net loss of $45.8 million due to increased R&D expenses, with $236.1 million in cash and equivalents. The stock price increased by 115.13% between February 4, 2025, and February 3, 2026.

As a clinical-stage biotechnology company, Solid Biosciences Inc. currently has no commercial product revenue, resulting in no traditional demand seasonality. The company's revenue streams are primarily from non-product sources like collaborative agreements, licensing deals, and government grants.

Solid Biosciences, Inc. is a precision genetic medicine company focused on developing gene therapy candidates for rare neuromuscular and cardiac diseases, operating within the life science sector. Its pipeline includes SGT-003 in Phase 1/2 for DMD, SGT-212 in Phase 1b for FA (with Orphan Drug designation), SGT-501 in preclinical phase for CPVT, SGT-601 in preclinical phase for TNNT2-mediated dilated cardiomyopathy, SGT-401 in preclinical phase for BAG3-mediated dilated cardiomyopathy, and SGT-701 in discovery phase for rare inherited diseases characterized by mutations in the RBM20 gene. The company also develops platform technologies, including capsid libraries, genetic regulators, immunomodulation technologies, manufacturing purity, and dual gene expression technology.

Solid Biosciences Inc. is headquartered in Charlestown, Massachusetts, and develops therapies in the United States.

Solid Biosciences generally holds a positive reputation within the investment community, particularly among analysts, with a consensus rating of "Strong Buy" from Wall Street analysts. Citizens has reiterated a "Market Outperform" rating. Zacks Investment Research rates Solid Biosciences as a "Hold". The company's active participation in international congresses and clinical trial forums, along with its focus on research and development for rare diseases, contributes to its scientific and medical reputation.

Solid Biosciences Inc. has 213 institutional owners and shareholders holding a total of 86,334,072 shares. Major institutional owners include Perceptive Advisors Llc, Bain Capital Life Sciences Investors, LLC, Siren, L.L.C., Ra Capital Management, L.p., BlackRock, Inc., Adage Capital Partners Gp, L.l.c., Vanguard Group Inc, Fmr Llc and Citadel Advisors Llc. Institutional ownership accounts for 81.46% of the stock, while individual insiders hold 1.90%.